205 related articles for article (PubMed ID: 32921987)
1. Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer.
Liu Y; Zhang N; Zhang H; Wang L; Duan Y; Wang X; Chen T; Liang Y; Li Y; Song X; Li C; Han D; Chen B; Zhao W; Yang Q
Drug Des Devel Ther; 2020; 14():3535-3545. PubMed ID: 32921987
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
3. Huaier extract synergizes with tamoxifen to induce autophagy and apoptosis in ER-positive breast cancer cells.
Qi W; Sun M; Kong X; Li Y; Wang X; Lv S; Ding X; Gao S; Cun J; Cai C; Wang X; Chen J; Yin A; Yang Q
Oncotarget; 2016 May; 7(18):26003-15. PubMed ID: 27027343
[TBL] [Abstract][Full Text] [Related]
4. Baicalein induces apoptosis and autophagy of breast cancer cells via inhibiting PI3K/AKT pathway in vivo and vitro.
Yan W; Ma X; Zhao X; Zhang S
Drug Des Devel Ther; 2018; 12():3961-3972. PubMed ID: 30510404
[TBL] [Abstract][Full Text] [Related]
5. Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma.
Ma J; Guo Y; Chen S; Zhong C; Xue Y; Zhang Y; Lai X; Wei Y; Yu S; Zhang J; Liu W
BMC Cancer; 2014 Mar; 14():172. PubMed ID: 24612549
[TBL] [Abstract][Full Text] [Related]
6. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
7. The Synergistic Effects of Celastrol in combination with Tamoxifen on Apoptosis and Autophagy in MCF-7 Cells.
Wang L; Tang L; Yao C; Liu C; Shu Y
J Immunol Res; 2021; 2021():5532269. PubMed ID: 34337076
[TBL] [Abstract][Full Text] [Related]
8. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
[TBL] [Abstract][Full Text] [Related]
9. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
Liu S; Meng X; Chen H; Liu W; Miller T; Murph M; Lu Y; Zhang F; Gagea M; Arteaga CL; Mills GB; Meric-Bernstam F; González-Angulo AM
Oncotarget; 2014 Oct; 5(19):9049-64. PubMed ID: 24979294
[TBL] [Abstract][Full Text] [Related]
10. IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
Kruger DT; Alexi X; Opdam M; Schuurman K; Voorwerk L; Sanders J; van der Noort V; Boven E; Zwart W; Linn SC
Int J Cancer; 2020 Apr; 146(8):2348-2359. PubMed ID: 31490549
[TBL] [Abstract][Full Text] [Related]
11. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S
Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer.
Watanabe T; Oba T; Tanimoto K; Shibata T; Kamijo S; Ito KI
PLoS One; 2021; 16(6):e0252822. PubMed ID: 34101751
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
14. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells.
Li F; Miao L; Xue T; Qin H; Mondal S; Thompson PR; Coonrod SA; Liu X; Zhang X
J Exp Clin Cancer Res; 2019 Oct; 38(1):414. PubMed ID: 31601253
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
17. Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
Yamamoto T; Kanaya N; Somlo G; Chen S
Breast Cancer Res Treat; 2019 Apr; 174(3):615-625. PubMed ID: 30607633
[TBL] [Abstract][Full Text] [Related]
18. Disruption of Cancer Metabolic SREBP1/miR-142-5p Suppresses Epithelial-Mesenchymal Transition and Stemness in Esophageal Carcinoma.
Huang CM; Huang CS; Hsu TN; Huang MS; Fong IH; Lee WH; Liu SC
Cells; 2019 Dec; 9(1):. PubMed ID: 31861383
[No Abstract] [Full Text] [Related]
19. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
[TBL] [Abstract][Full Text] [Related]
20. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
